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AbstrACt
Introduction Effective interventions to promote upper-
limb recovery poststroke are characterised by intensive 
and repetitive movements. However, the repetitive nature 
of practice may adversely impact on adherence. Therefore, 
the development of rehabilitation devices that can be used 
safely and easily at home, and are motivating, enjoyable 
and affordable is essential to the health and well-being 
of stroke survivors. The Neurofenix platform is a non-
immersive virtual reality device for poststroke upper-limb 
rehabilitation. The platform uses a hand controller (a 
NeuroBall) or arm bands (NeuroBands) that facilitate 
upper-limb exercise via games displayed on a tablet. The 
Rehabilitation via HOMe Based gaming exercise for the 
Upper-limb post Stroke trial aims to determine the safety, 
feasibility and acceptability of the Neurofenix platform for 
home-based rehabilitation of the upper-limb poststroke.
Methods and analysis Thirty people poststroke will 
be provided with a Neurofenix platform, consisting of a 
NeuroBall or NeuroBands (dependent on impairment level), 
seven specially designed games, a tablet and handbook 
to independently exercise their upper limb for 7 weeks. 
Training commences with a home visit from a research 
therapist to teach the participant how to safely use the 
device. Outcomes assessed at baseline and 8 weeks and 
12 weeks are gross level of disability, pain, objectively 
measured arm function and impairment, self-reported 
arm function, passive range of movement, spasticity, 
fatigue, participation, quality of life (QOL) and health 
service use. A parallel process evaluation will assess 
feasibility, acceptability and safety of the intervention 
through assessment of fidelity to the intervention 
measured objectively through the Neurofenix platform, 
a postintervention questionnaire and semistructured 
interviews exploring participants’ experiences of the 
intervention. The feasibility of conducting an economic 
evaluation will be determined by collecting data on QOL 
and resource use.
Ethics and dissemination Ethics approval granted 
from Brunel University London (10249-MHR-
Mar/2018-12322-2). Trial results will be submitted 
for publication in journals, presented at national and 
international conferences and distributed to people with 
stroke.
trial registration number ISRCTN60291412; Pre-results. 
IntroduCtIon 
Stroke is the leading cause of severe disability 
worldwide with approximately 17 million new 
strokes each year.1 2 The UK has 1.2 million 
stroke survivors with 110 000 first-time 
strokes occurring each year resulting in an 
estimated societal cost of £26 billion per 
year.1 2 Following stroke, 85% of people 
initially experience upper-limb weakness, and 
of those with minimal movement on hospital 
admission, only 11%–14% regain full func-
tion of their arm.2–4 This loss in upper-limb 
function results in increased dependence and 
decreased quality of life (QOL).5 Reduced 
upper-limb function has been identified as 
a strong predictor of lowered psycholog-
ical well-being poststroke.5 6 Innovation and 
investigation of effective treatments for arm 
recovery has been identified as a priority for 
stroke research.7 
strengths and limitations of this study
 ► The Rehabilitation via HOMe Based gaming exercise 
for the Upper-limb post Stroke trial will investigate 
the feasibility, acceptability and safety of a novel 
gaming platform (the Neurofenix platform) at home 
for upper-limb exercise after stroke.
 ► Upper-limb activity data will be objectively mea-
sured by the device. Assessment outcome measures 
include objective (assessed blind to timepoint) and 
self-reported measures.
 ► To be maximally inclusive, stroke survivors with 
moderate to severe arm impairment will be included 
in the study.
 ► The feasibility of conducting an economic evaluation 
will be determined by collected data on quality of life 
and resource use.
 ► This is a home-based intervention study; thus, par-
ticipants and researchers collecting the data will not 
be blinded.
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Evidence indicates the most effective interventions to 
improve upper-limb function are characterised by high 
intensity and repetitive practice.8 A higher intensity and 
frequency of upper-limb stroke rehabilitation is associ-
ated with improved QOL,9 motor function and ability to 
perform activities of daily life10 and is cost-effective.11 The 
UK quality standard for stroke advises 45 min of each rele-
vant therapy for a minimum of 5 days a week.11 However, 
a 2015 UK national stroke audit showed on average most 
hospitals are unable to meet this quality standard.12 
Specifically, time spent retraining the upper limb is very 
low, with an average of 32 repetitions per rehabilitation 
session.13 14 As such, there is a growing emphasis on the 
stroke survivor exercising independently without the 
presence of a therapist. However, adherence to home 
exercise is known to be poor.15 16 A perceived lack of 
support and feedback along with boredom with exercises 
are the most frequently cited factors associated with poor 
compliance.17 18
Virtual reality (VR)-based activities have been suggested 
as an intervention to improve upper-limb recovery by 
providing motivating environments or gameplay to facil-
itate rehabilitation.19 This digital health solution helps 
address boredom and compliance problems, can facilitate 
increased time in therapy and may not be reliant on ther-
apist contact time.19 20 In addition, the ability of VR activi-
ties to provide feedback may enhance motor learning.21 22 
Visual feedback via an on-screen character (avatar) can 
activate mirror neurones, which may aid recovery from 
stroke.23 24
VR can be considered in terms of the level of immer-
sion provided, that is, the degree the user feels present 
in the virtual world due to the technical aspects of the VR 
environment. Immersive systems can generate life-scaled, 
three-dimensional images, with surround sound auditory 
and sensory feedback such as vibration, and pressure,25 
whereas non-immersive systems involve two-dimensional 
images typically viewed on a screen with interaction being 
via controller-based systems (such as computer keyboards, 
joysticks, balance boards and handheld devices) or via 
camera-based tracking systems.26 Non-immersive systems 
are more commonly used for rehabilitation as they have 
smaller space requirements, cost less and have fewer side 
effects (eg, motion sickness).27
The Neurofenix platform is a non-immersive device 
designed to enable and encourage stroke survivors to 
independently exercise their upper limb with minimal 
therapist input. The platform was developed by Neuro-
fenix, a bioengineering enterprise ( www. neurofenix. 
com), along with stroke survivors and neurological phys-
iotherapists. The platform consists of a hand controller 
or armbands, seven specially designed games, a tablet and 
an instruction handbook.
study aims and objectives
This study aims to determine the safety, feasibility and 
acceptability of the Neurofenix platform for home-based 
rehabilitation of the upper-limb poststroke. A secondary 
aim is to test procedures to inform a definitive randomised 
controlled trial to assess the clinical and cost-effectiveness 
of the Neurofenix platform with stroke survivors. The 
study objectives are:
1. To assess the safety, feasibility and acceptability of us-
ing the Neurofenix platform intervention at home for 
the rehabilitation of the upper limb after stroke.
2. To assess the feasibility of conducting a definitive trial 
of the clinical and cost-effectiveness of the Neurofenix 
platform intervention.
3. To understand the factors relating to people with 




The Rehabilitation via HOMe Based gaming exercise for 
the Upper-limb post Stroke study is a non-randomised 
intervention trial (figure 1). A total of 30 participants will 
be recruited to use the Neurofenix platform at home for 
7 weeks (1 week training, 6 weeks exercise). Assessments 
will be performed at baseline and 8 and 12 weeks. A 
parallel process evaluation will assess the safety, feasibility 
and acceptability of the intervention and the feasibility 
of conducting a definitive trial. Semistructured interviews 
will be used to explore the perspectives of participants 
receiving this complex intervention.
study setting
The Department of Clinical Sciences, Brunel University 
London will coordinate the study. Assessments will be 
conducted, and the intervention delivered in partici-
pants’ homes.
trial status




 ► Aged 18 or over
 ► Capacity to consent
 ► Self-reported diagnosis of stroke (unilateral haemor-
rhagic or ischaemic)
 ► 12 weeks minimum poststroke and finished formal 
rehabilitation for their arm, that is, National Health 
Service (NHS) or private provider
 ► Mild to severe reduction in arm function poststroke, 
estimated by a Motricity Index28 score between 
9 and 25 for elbow and shoulder movement
 ► Able to sit or stand independently (using an aid if 
necessary) for a minimum of 5 min
 ► Can communicate in English, that is, sufficient for 
completion of trial intervention and assessment
Exclusion criteria
 ► Unstable medical conditions
 ► Uncontrolled photosensitive epilepsy
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 ► Acquired brain injury from other causes, bilateral or 
cerebellar lesions
 ► Uncompensated visual neglect, hemianopia or uncor-
rected visual field deficits (assessed by the National 
Institutes of Health Stroke Scale)29
 ► Pre-existing, unremitting arm pain at rest
sample size
This is a feasibility study and no power calculation for the 
primary outcome(s) is required. The primary analytic 
aim is to evaluate the safety, feasibility and acceptability 
via the process evaluation data.
recruitment
Participants will be recruited from Brunel’s estab-
lished database of people with stroke who have 
consented to contact about future stroke research 
studies and the ISRCTN Registry website. Participants 
will also be recruited through Different Strokes and 
the Action for Rehabilitation in Neurological Injury 
Institute. These participants will be accessed via gate-
keepers and informed written consent will be taken 
by research therapists (see online supplementary 
appendices A, B and C for examples of the informed 
consent materials used).
Figure 1 Rehabilitation via HOMe Based gaming exercise for the Upper-limb post Stroke (RHOMBUS) trial design.
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Recruitment will run from April 2018 to August 2018. 
Thirty participants will be recruited over 5 months, 
equating to approximately 1.5 participants per week.
reasons for non-participation
A non-participation questionnaire will be distributed to 
those who do not wish to participate in the study. This 
will help identify reasons for refusal and any differences 
in baseline characteristics between participants and 
non-participants.
Intervention
The Neurofenix platform is a portable non-immersive 
VR device for gamification of upper-limb stroke rehabil-
itation. The platform uses either a hand controller, the 
NeuroBall or armbands, NeuroBands, to promote specific 
practice of movements in the shoulder, elbow, wrist and/
or hand through uniquely designed games displayed on a 
tablet. To ensure adequate reporting of the intervention 
a Template for Intervention Description and Replication 
checklist was completed (table 1).
This study will examine the Neurofenix platform 
intervention over a 7-week period, commencing with 
a home visit from a research therapist. The participant 
will be given the Neurofenix platform (see table 1 for 
content details) and trained how to use their device inde-
pendently or with the help of a carer (if requested). The 
participant will then be advised to use the platform with 
an aim of 45 min a day, 5 days a week or more if they are 
able, self-limiting use based on fatigue and pain, and 
slowly increasing their use of the device over the first 
week. Participants will be advised to contact the research 
therapists as necessary for clinical and technical support 
throughout the intervention. A more detailed descrip-
tion of the intervention process can be found in table 1.
Assessments
Assessments will be completed in the participant’s 
home at baseline and 8 and 12 weeks postintervention 
commencement. All participants will be requested to 
complete follow-up assessments, including those who 
withdraw or were withdrawn from the intervention. 
Those participants will also be asked to complete a ques-
tionnaire to identify reasons for withdrawal. The assess-
ment lasts approximately 2 hours and regular breaks will 
be given to mitigate fatigue and burden. In addition to 
the stated outcomes, further information will be collected 
on at baseline on socioeconomic status, stroke and rele-
vant medical history and lifestyle factors.
outcomes
All outcome measures follow a standardised operating 
procedure.
Objectively measured arm function
Arm function will be objectively assessed using the 
Action Research Arm Test (ARAT). The ARAT assesses 
upper-limb function using observational methods and is 
divided into four subtests of grasp, grip, pinch and gross 
arm movement. Performance on each item is rated on 
a four-point ordinal scale from 0 to 3 with a maximum 
score of 57, a higher score indicating a better level of 
function. The ARAT has excellent inter-rater reliability in 
chronic stroke populations30–32 and excellent test–retest 
reliability, moderate construct validity and responsive-
ness.30 The ARAT has a minimally clinically important 
difference (MCID) in people with chronic stroke of 5.7 
points, equivalent to roughly 10% of the measure’s total 
range.31 The ARAT has been shown to have floor and 
ceiling effects and a moderate burden.30 Completion of 
the ARAT at each timepoint will be videoed for blinded 
assessor scoring at a later date.
Objectively measured arm impairment
The Fugl-Meyer Assessment-upper limb (FMA-UL) will 
assess arm impairment. Performance is rated on a three-
point ordinal scale from 0 to 2, with a maximum score of 
66, a higher score indicates minimal or no impairment. 
The FMA-UL has excellent inter-rater reliability when 
used in the chronic stroke population.33 MCID ranges 
from 4.25 to 7.25 depending on different facets of upper-
limb movement.34
Passive range of movement
Passive range of movement of the upper limb will be 
assessed for the shoulder, elbow, wrist, thumb and index 
finger using goniometry to increase the inter-rater reli-
ability of these measurements.35
Spasticity
The Modified Modified Ashworth Scale (MMAS) will 
assess for spasticity. The MMAS tests resistance to passive 
movement of a joint with varying degrees of velocity. 
Performance is rated on a six-point ordinal scale from 0 
to 5 with a higher score indicating higher spasticity.36 The 
MMAS has good to very good intra-rater and inter-rater 
reliability for the elbow and wrist flexors.37 38
Self-reported arm function
Self-reported arm use will be assessed using the 28-item 
Motor Activity Log (MAL). The MAL is a semistructured 
interview where individuals are asked to rate the amount 
of movement during 28 daily functional tasks. The MAL 
has excellent test–retest reliability in chronic stroke 
patients.39 The MCID is 1.0–1.1.40 A higher score on the 
amount of use scale indicates the respondent’s ability to 
use the stroke-affected arm is closer to their prestroke 
ability.
Fatigue
Fatigue will be assessed using the seven-item Fatigue 
Severity Scale (FSS-7). This questionnaire explores how 
fatigue interferes with stated activities, the participant 
rates the severity on a seven-point Likert scale for each 
item. The FSS-7 is recommended as it has better validity 
and reliability and is likely more sensitive for measuring 
change in fatigue in people with stroke.41 Minimum score 
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is 7 and maximum 49, a higher score indicates a greater 
impact of fatigue on a person’s activities.
Quality of life
QOL will be assessed using the EuroQol 5 Dimensions 5 
Levels (EQ-5D-5L). The EQ-5D-5L describes and values 
health in five dimensions: mobility, self-care, usual activ-
ities, pain/discomfort and anxiety/depression.42 Each 
dimension has five response categories ranging from no 
problems to extreme problems. Participants also rate 
their overall health on the day of the interview on a visual 
analogue scale from 0 to 100 (EuroQol-Visual Analogue 
Scale).42 In people with stroke, the EQ-5D-5L has been 
shown to have reasonable concurrent validity (ρ=0.255–
0.703, p<0.05), acceptable responsiveness and a MCID of 
0.10.43
Participation
Participation will be assessed using the 10-item Subjective 
Index of Physical and Social Outcome (SIPSO).44 The 
SIPSO measures factors relating to physical functioning/
mobility and social/emotional functioning. The SIPSO is 
a valid and reliable measure of social and physical inte-
gration in people with stroke,44 with a higher internal 
construct validity when the subscales are used, instead 
of the total scale.45 Each question is scored from 0 to 4; 
minimum score of 0 and maximum of 40, a higher score 
indicates an increased ability to reintegrate to a ‘normal’ 
lifestyle.
Pain
Pain will be assessed using a visual analogue scale (VAS) 
from 0, no pain, to 10, excruciating pain, over the last 
7 days. A VAS is a valid measure of pain intensity and is 
responsive to change.46 47 To help those with language 
or mild cognitive problems, the scale is illustrated with 
emotive faces.
Gross level of disability
The simplified modified Rankin Scale questionnaire 
(smRSq) will be used to measure the participant’s level 
of disability. The smRSq requires yes or no answers from 
a patient or caregiver. The smRSq has excellent reli-
ability by telephone (κ=0.76 (0.63 to 0.90)) and in person 
(κ=0.71 (95% CI 0.57 to 0.86)) and correlates with QOL 
and initial stroke severity.48 49
Health service use
A modified version of the Client Service Receipt Inven-
tory (CSRI) will assess health service use. The CSRI 
collects retrospective information on service utilisation, 
service-related issues and income.50 The CSRI has been 
successfully used to estimate service use among adults 
with stroke.51
Fidelity to use of the Neurofenix platform
Fidelity to use of the Neurofenix platform will be assessed 
objectively using data collected via the sensors in the 
NeuroBall and NeuroBands and the software on the 
tablet. These automatically collect data on the time spent 
actively exercising in each game and the number of move-
ment repetitions.
Clinical and technical support provided
The amount of clinical and technical support will be 
recorded by the research therapists: the number, length 
and content of all calls and visits with participants.
Economic evaluation
This study will assess the feasibility of conducting an 
economic evaluation alongside a definitive clinical effec-
tiveness of the Neurofenix platform. The aim of this feasi-
bility study is to examine the practicality of collecting 
resource use and QOL data, the quality of the data and 
the amount of missing data observed. Resource use will 
include the following: therapist training; training home 
visits; clinical and technical support; participants’ out-of-
pocket expenses related to any additional exercise being 
undertaken; and health and personal social service use. 
These will be collected through diaries, management 
records, questionnaires and interviews.
In the definitive trial, the economic evaluation will take 
NHS, personal social services and participants’ perspec-
tive.52 The main outcome of the economic analysis will be 
an incremental cost per quality-adjusted life-year (QALY), 
based on EQ-5D-5L. Unit costs will be taken from the 
NHS reference costs (eg, DH 2016), standard unit costs 
(eg, PSSRU 2015) and published literature.
Process evaluation
A parallel process evaluation will be conducted alongside 
the trial to determine the feasibility, acceptability and 
safety of the intervention. The feasibility of delivering 
the intervention will be assessed through multiple mech-
anisms following the guidelines for fidelity in complex 
rehabilitation interventions.53 Specifically, feasibility and 
perceived adequacy of training the research therapists 
will be assessed by analysis of their field notes. Feasi-
bility of delivering the training session, clinical or tech-
nical calls and visits, and carrying out assessments will be 
determined by number, length and content of training 
sessions, the clinical and technical call and visit logs and 
therapists’ field notes on assessment and intervention 
participant burden.
The feasibility and acceptability of the intervention for 
people with stroke will be assessed by evaluating the distri-
bution of fidelity to the intervention, as measured by the 
Neurofenix platform, in terms of duration of active game 
play. Associations between participant-related factors, 
such as level of impairment, and fidelity will be explored. 
In addition, participant-reported experience will be 
investigated using the pretraining and post-training 
questionnaires, postintervention questionnaire, and by 
conducting semistructured interviews, as described next.
Pretraining and post-training questionnaire
Each participant will complete a pretraining question-
naire prior to the training session to explore previous 
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experience with technology and gaming and to measure 
confidence levels with new technology. A post-training 
questionnaire will be completed after the training session 
to assess their confidence level with using the Neurofenix 
platform and to explore how the participant might use 
the device in the following weeks.
Postintervention questionnaire
A postintervention questionnaire will be conducted after 
completion of the intervention period to assess the partic-
ipant’s perception of the Neurofenix platform and its 
components.
Interviews
Semistructured interviews will be conducted with a purpo-
sive sample of 18 participants to explore the perspectives 
of those receiving the intervention. Sampling will involve 
key criteria such as gender, age, device used (NeuroBall 
or the NeuroBands), amount of use (use of the device 4 
or more days a week pragmatically classified as high use, 
3 or less as low use), level of upper-limb impairment and 
function (ARAT scores 0–9 as severe, 10–21 as moderately 
severe, 22–43 as moderate, 43–53 as mild and 55–57 as 
full).54
Interviews will be conducted at the participant’s house 
by a researcher trained in qualitative research methods. 
Topic guides developed from relevant literature and the 
specific aims of the process evaluation will be used. Where 
possible, the participant will be interviewed by a research 
therapist not involved in the intervention training to 
reduce the risk of socially desirable responses.
Safety
Pain and fatigue will be assessed at baseline, 8 weeks and 
12 weeks. Self-reported pain will be assessed using a pain 
VAS and asking the average pain over the last week, the 
section relating to pain in the EQ-5D-5L. Fatigue will 
be assessed using the FSS-7. The number of episodes of 
pain, falls, fatigue, eye strain and other reported adverse 
events will be collated to assess the safety of the interven-
tion. Research therapists will proactively enquire about 
changes in the participant’s health or any compromises 
of safety since the last contact. A record of the incidence 
of adverse events from baseline measures until the end of 
the trial for each participant will be maintained. Falls inci-
dence will be determined by asking participants at each 
contact point if they have fallen or tripped since the last 
contact. Although this method of assessing falls relies on 
the recall ability of the participant, it accurately detects 
injurious falls in community-dwelling older adults.55 An 
adverse event is considered serious if it results in death, 
is life-threatening, requires hospitalisation or prolonga-
tion of existing hospitalisation and results in persistent or 
significant disability or incapacity. Participants who expe-
rience a serious adverse event will be withdrawn from the 
study.
A summary of all data collected and when these are 
collected is provided in table 2.
data management
Personal data collected during the trial will be handled 
and stored in accordance with the 1998 Data Protection 
Act and the General Data Protection Regulation 2018. 
Consent forms will be kept separate from other data 
in site trial master files at Brunel University London in 
a locked, secure environment. To preserve participant 
anonymity, only their allocated trial number and initials 
will be recorded on trial documentation (except the 
consent form). Confidentiality of all participant data 
will be maintained and information by which a partici-
pant could be identified will not be disclosed to a third 
party. Only non-identifiable clinical data will be shared 
with Neurofenix. Neurofenix will automatically collect 
data from the Neurofenix platform including user name, 
active game play and number of movement repetitions. 
Data generated by the Neurofenix platform will adhere 
to a Data Privacy Protocol, informed by Information 
Commissioner’s Office guidelines and is compliant with 
the General Data Protection Regulation.
Use of study data will be controlled by the principal 
investigator. All data and documentation related to the 
trial will be stored in accordance with applicable regula-
tory requirements and access to data will be restricted to 
authorised trial personnel.
Qualitative interviews will be audio recorded and will be 
stored electronically and identified by trial number only. 
Transcripts will be anonymised or assigned a pseudonym; 
files will be stored using password-protected files. The 
ARAT video recordings will be stored electronically on 
encrypted and password-protected devices and identified 
by trial number only. Pseudonymised quantitative data 
will be made available in a public repository following 
publication of findings.
Patient and public involvement
People with stroke have been involved in the ongoing 
development of the intervention, including 18 stroke 
survivors who participated in an earlier study examining 
the usability of the Neurofenix platform. Two additional 
stroke survivors have provided input to the protocol, 
reviewed trial documentation, including participant 
information sheets, participant invite letters and ques-
tionnaires. The stroke survivors will continue to advise 
the research team throughout the trial, including dissem-
ination of the results.
data analysis
Qualitative data
To determine the feasibility, acceptability and safety of 
the intervention with people poststroke, interviews will 
be analysed using framework analysis.56 This method 
provides a strong audit trail of the analytical process, 
which enhances transparency.57 The technique involves 
five iterative stages: familiarisation, identifying thematic 
framework, labelling, charting and mapping and inter-
pretation, following which significant themes can be 
presented.57 As a further step to enhance rigour in this 
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process, three researchers will independently code the 
same three transcripts and then meet to discuss and agree 
on codes assigned to each passage and their definitions.
Quantitative data
Distribution of the data will be examined using histo-
grams, Q-Q plots and cross-tabulations. Descriptive statis-
tics will be used to report pain and fatigue at baseline 
and follow-up, the number of participants experiencing 
adverse events during follow-up and the number of 
adverse events per participant. Generalised estimating 
equations will be used to examine change in pain and 
fatigue across timepoints.
Descriptive statistics will be used to report all data 
relating to fidelity, feasibility and acceptability of the 
intervention including the number and duration of clin-
ical and technical calls, average session length and time 
spent in each game, enjoyment of games and number 
of episodes of pain experienced during intervention. 
Recruitment, retention and outcome measure comple-
tion will be described using frequencies and percentages.
Descriptive statistics will be used to report key partic-
ipant characteristics across levels of fidelity to the inter-
vention in terms of frequency and duration of active 
game play. Participant characteristics will include level 
of disability, pretraining confidence in using new tech-
nology, post-training confidence in using the NeuroBall/
Bands, level of support provided to use the NeuroBall/
Bands and age.
The practicality, quality of data, quantity of missing 
data and reasons for missing data associated with the data 
collection tools will be recorded as part of determining 
the feasibility of conducting a phase three trial.
timeline
The trial is funded for a period of 14 months and 
commenced in January 2018. Recruitment commenced 
in April 2018 and will be completed in August 2018. The 
final follow-up assessment is projected to be completed in 
October 2018 with data analysis and report writing being 
conducted from October onwards.
Ethics
The study is sponsored by Brunel University London 
and will be conducted in accordance with the approved 
protocol. Any protocol modifications will be notified to 
the Brunel University London Ethics Committee and 
consent will be reobtained from participants if required. 
The principles of the Declaration of Helsinki and Good 
Clinical Practice guidelines will be adhered to, along with 
Table 2 Schedule of assessments and outcome measures
Clinical assessments Preintervention Intervention Eight weeks Postintervention Twelve weeks
Informed consent X
Sociodemographic measurement X
ARAT X X X
FMA-UL X X X
PROM-UL X X X
MAL X X X
FSS-7 X X X
SIPSO X X X
smRSq X X X
Pain VAS X X X
EQ-5D-5L X X X
CSRI X X X
Training and training questionnaire X
Neurofenix platform use X 
Clinical and technical support X 
Postintervention questionnaire X X
Semistructured interview X X
Falls X X X X
Upper-limb pain X X X X
AE and SAE X X X X
AE, adverse event; ARAT, Action Research Arm Test; CSRI, Client Service Receipt Inventory; FMA-UL, Fugl-Meyer Assessment-upper 
limb; FSS-7, seven-item Fatigue Severity Scale; MAL, Motor Activity Log; PROM-UL, passive range of movement-upper limb; SAE, serious 
adverse event; SIPSO, Subjective Index of Physical and Social Outcome; smRSq, simplified modified Rankin Scale questionnaire; VAS, visual 
analogue scale; EQ-5D-5L, EuroQol 5 Dimensions 5 Levels.
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UK legislation and Brunel University Research integrity 
guidance.
Monitoring
As the intervention is low risk and the potential harm 
is not anticipated, there will be no Data Monitoring 
Committee, interim analyses or stopping rules.
Administrative structures
The trial will be run by the principal investigator, coin-
vestigators and two research therapists. The Chair of the 
College Research Ethics Committee will provide addi-
tional trial oversight, along with quarterly monitoring 
meetings with the funder and Neurofenix. Financial 
accounts will be externally audited.
dissemination
The dissemination plan will be developed in the early 
phases of the trial and will involve social media, broad-
cast media, the internet and electronic mail as well as 
more traditional routes, that is, peer-reviewed journal 
and national and international conferences. Publications 
will follow the Enhancing the Quality and Transparency 
of Health Research guidelines for reporting non-ran-
domised studies. Authorship will follow international 
guidelines (International Committee of Medical Journal 
Editors criteria). The results will be disseminated to all 
participants and to those who wanted to participate but 
did not meet the inclusion criteria and who agreed to be 
contacted for research purposes.
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